AstraZeneca Completes Purchase of Sumitomo Chemical's Stake in AstraZeneca K.K. (Japan)
26 March 2014
AstraZeneca today announced it has completed the purchase of Sumitomo Chemical's remaining shares in AstraZeneca K.K.
The purchase was valued at approximately JPY10 billion ($102 million) and gives AstraZeneca control of the entire shareholding of AstraZeneca K.K.
Marc Dunoyer, Chief Financial Officer, AstraZeneca, said: "Our decision to gain full control of AstraZeneca K.K. reinforces our focus on Japan as a key growth platform."
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)
Investor Enquiries
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882
Anthony Brown +44 20 7604 8067 mob: +44 7585 404943
Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729